Document Detail


Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
MedLine Citation:
PMID:  11579345     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The ACE Inhibitor After Anthracycline (AAA) study is a randomized, double-blind, controlled clinical trial comparing enalapril with placebo to determine whether treatment can slow the progression of cardiac decline in patients who screen positive for anthracycline cardiotoxicity. METHODS: The primary outcome measure is the rate of decline, over time, in maximal cardiac index (in liters per minute per meters squared) at peak exercise; the secondary outcome measure is the rate of increase in left ventricular end systolic wall stress (in grams per centimeters squared). Patients >2 years off therapy and <4 years from diagnosis, aged 8 years and older, were eligible if they had received anthracyclines and had at least one cardiac abnormality identified at any time after anthracycline exposure. RESULTS: A total of 135 patients were randomized to enalapril or placebo. Baseline characteristics were similar across treatment groups. CONCLUSIONS: The AAA study will provide important information concerning the efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracycline cardiotoxicity.
Authors:
J H Silber; A Cnaan; B J Clark; S M Paridon; A J Chin; J Rychik; A N Hogarty; M I Cohen; G Barber; M Rutkowsky; T R Kimball; C Delaat; L J Steinherz; H Zhao; M R Tartaglione
Related Documents :
8800725 - University of wisconsin solution versus stanford cardioplegic solution and the developm...
20103775 - The effects of vitamin d supplementation on physical function and quality of life in ol...
20525985 - Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with...
16290975 - Pilot study to determine the impact of a multidisciplinary educational intervention in ...
22406775 - Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled ...
23241665 - Short- and medium-term impact of a residential weight-loss camp for overweight adolesce...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  American heart journal     Volume:  142     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-01     Completed Date:  2001-12-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  577-85     Citation Subset:  AIM; IM    
Affiliation:
Division of Pediatric Oncology, Department of Pediatrics, Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Silber@email.chop.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Algorithms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Anthracyclines / adverse effects*,  therapeutic use
Child
Child, Preschool
Disease Progression
Double-Blind Method
Enalapril / adverse effects,  therapeutic use*
Female
Heart Diseases / chemically induced*,  diagnosis,  prevention & control*
Heart Function Tests
Humans
Infant
Male
Neoplasms / drug therapy*
Placebos
Research Design / standards
Statistics, Nonparametric
Grant Support
ID/Acronym/Agency:
CA-16520/CA/NCI NIH HHS; M01-RR-00240/RR/NCRR NIH HHS; R01 HL-50424/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anthracyclines; 0/Placebos; 75847-73-3/Enalapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Seven cases of surgical native valve endocarditis caused by coagulase-negative staphylococci: An und...
Next Document:  Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-o...